Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03753919
Title Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial (DUTHY)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Grupo Espanol de Tumores Neuroendocrinos

thyroid gland papillary carcinoma

thyroid gland Hurthle cell carcinoma

thyroid gland cancer

thyroid gland medullary carcinoma

thyroid gland follicular carcinoma

thyroid gland anaplastic carcinoma

differentiated thyroid gland carcinoma


Durvalumab + Tremelimumab

Age Groups: adult | senior
Covered Countries ESP

Facility Status City State Zip Country Details
Instituto Catalán de Oncología de Hospitalet Recruiting L'Hospitalet de Llobregat Barcelona 08908 Spain Details
Hospital Provincial de Castellón Recruiting Castelló Valencia Spain Details
Hospital Clínic Barcelona Recruiting Barcelona Spain Details
Hospital Universitari Vall d'Hebron Recruiting Barcelona Spain Details
MD Anderson Cancer Center Recruiting Madrid 28033 Spain Details
Hospital Clínico San Carlos Recruiting Madrid Spain Details
Hospital Universitario 12 de Octubre Recruiting Madrid Spain Details
Hospital Universitario HM Sanchinarro Recruiting Madrid Spain Details
Hospital Universitario La Paz Recruiting Madrid Spain Details
Hospital Universitario Ramón y Cajal Recruiting Madrid Spain Details
Hospital General Universitario Morales Meseguer Recruiting Murcia Spain Details
Hospital Universitario Virgen de la Victoria Recruiting Málaga Spain Details
Clínica Universidad de Navarra Recruiting Pamplona Spain Details
Instituto Valenciano de Oncología Recruiting Valencia 46009 Spain Details
Complejo Hospitalario Universitario de Vigo (CHUVI) Recruiting Vigo 36036 Spain Details
*Shaded cells indicate that there was no data available from for the field